Tumor-Informed Circulating Tumor DNA (ctDNA) in Advanced NSCLC Treated with Pembrolizumab ± Chemotherapy
Year: 2025
Type: article
Abstract: Introduction: Currently available biomarkers lack precision in predicting which patients with advanced non-small cell lung cancer (NSCLC) will benefit from first-line immunotherapy strategies. An early pharmacodynamic indicator of resistance could enable timely treatment adaptation. This study aimed to evaluate whether early changes in circulating tumor DNA (ctDNA) after initiating pembrolizumab ± chemotherapy can predict treatment response prior to imaging.
Source: The Journal of Liquid Biopsy
Authors: Diego Enrico, Gisela Vargas, Gabriela Wulfson, Florencia Tsou, Delfina Peralta Tanco, Carmen Pupareli, Federico Waisberg, Milena Revelli Ling, Matías Chacón, Claudio Martín
Institution: Instituto Alexander Fleming
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,080
OpenAlex ID: W4416630753